News Quantified

APVO – aptevo therapeutics inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Aptevo Therapeutics jumps after securing $60 million equity line of credit [Seeking Alpha]

Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality [Yahoo! Finance]

Aptevo Therapeutics (NASDAQ:APVO) had its "sell (e)" rating reaffirmed by analysts at Weiss Ratings.

Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors [Yahoo! Finance]

Aptevo Therapeutics (NASDAQ:APVO) had its "sell (e)" rating reaffirmed by analysts at Weiss Ratings.

Form 8-K Aptevo Therapeutics Inc. For: Jan 08

Form 8-K Aptevo Therapeutics Inc. For: Dec 09

Form EFFECT Aptevo Therapeutics Inc.

Form 424B4 Aptevo Therapeutics Inc.

Form 4 Aptevo Therapeutics Inc. For: Nov 10 Filed by: Grant Grady III

Top News Gainers

3/10 Aptevo Therapeutics Inc (NASDAQ: APVO) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 20.5%

3/16 Aptevo Therapeutics Provides Update On Ongoing APVO436 Phase 1 Clinical Trial 19.1%

4/13 Form 8-K Aptevo Therapeutics Inc. For: Apr 13 15.2%

10/3 Form 8-K Aptevo Therapeutics Inc. For: Oct 03 11.6%

3/18 Aptevo Therapeutics Inc (NASDAQ: APVO) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 11.2%

11/4 Form 8-K Aptevo Therapeutics Inc. For: Nov 01 8.8%

2/28 Aptevo Therapeutics Sells IXINITY Hemophilia B Therapy for Estimated Proceeds in Excess of $100 Million 7.5%

11/8 Aptevo Therapeutics and Alligator Bioscience Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer 2019 Annual Meeting 7.4%

4/23 Aptevo Therapeutics Inc (NASDAQ: APVO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.7%

8/19 Form 4 Aptevo Therapeutics Inc. For: Aug 16 Filed by: Maddux Randy Joe 5.6%

Top News Decliners

2/13 Form SC 13G/A Aptevo Therapeutics Inc. Filed by: RENAISSANCE TECHNOLOGIES LLC -20.0%

3/13 Form 8-K Aptevo Therapeutics Inc. For: Mar 11 -14.5%

8/12 Form 424B5 Aptevo Therapeutics Inc. -13.5%

3/2 Form 8-K Aptevo Therapeutics Inc. For: Feb 28 -12.3%

1/31 Form PRE 14A Aptevo Therapeutics Inc. For: Mar 11 -12.0%

8/9 Q2/2019 6/30/2019 EPS -0.300 ZacksConsensus -0.380 ActVsEst 0.080 - Beat -11.2%

3/5 Aptevo Therapeutics Inc (NASDAQ: APVO) had its "buy" rating re-affirmed by analysts at Roth Capital. -7.0%

10/16 Form 8-K Aptevo Therapeutics Inc. For: Oct 11 -6.9%

3/25 Aptevo Therapeutics Reports 2019 Financial Results and Provides Business Update -6.9%

7/25 Aptevo Therapeutics Reports Continued Progress In APVO210 and APVO436 Clinical Trials -6.4%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day